Advertisement

Topics

Companies Related to "Opioid patients face several barriers treatment study finds" [Most Relevant Company Matches] RSS

14:30 EST 10th December 2018 | BioPortfolio

Here are the most relevant search results for "Opioid patients face several barriers treatment study finds" found in our extensive corporate database of over 50,000 company records.

Showing "Opioid patients face several barriers treatment study finds" Companies 1–25 of 6,700+

Relevant

CleanSlate Centers

A pioneer and leader in outpatient addiction medicine, CleanSlate Centers is a national medical group which provides treatment for the chronic disease of addiction, primarily opioid and alcohol use disorders. Founded in 2009 in response to the growing opioid epidemic facing the country, the company operates a growing network of physician-led, office-based ...


The Opioid Center of Support

Vera Bullock founded The Opioid Center of Support to develop solutions to the opioid crisis for caregivers. After her son Justin Solak died from an opioid overdose at the age of 25, Vera set out with a mission to help others suffering with a loved one coping with misuse. Having personally experienced the frustration of trying to find credible resources to ...

Reckitt Benckiser Pharmaceuticals Inc.

Reckitt Benckiser Pharmaceuticals Inc. is a specialty pharmaceutical company that markets SUBOXONE(R) (buprenorphine HCl/naloxone HCl dihydrate [2 mg/0.5 mg and 8 mg/2 mg]) C-III Sublingual Tablets and SUBUTEX(R) (buprenorphine HCl [2 mg and 8 mg]) C-III Sublingual Tablets, formulations of buprenorphine used to treat opioid dependence in a medical office-based setting. SUBOXONE(R) and SUBUTEX(R),...


ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

The Body The Complete HIV/AIDS Resource

The Body's mission is to:Use the Web to lower barriers between patients and clinicians. Demystify HIV/AIDS and its treatment. Improve patients' quality of life. Foster community through human connection.

Priska

Priska™ is designed to provide assessment data associated with a patient’s risk for opioid abuse, as well as other mental health conditions. The Opioid Risk Tool assessment consists of a 5-question survey and fits each patient into one of three risk categories: low risk, moderate risk or high risk. The peer-reviewed tool is highly trusted and wid...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

WAISMANN METHOD®

WAISMANN METHOD® is pioneering opiate treatment based on a safe and proven protocol that utilizes the most advanced medical techniques available. A major center for opioid dependency, treatment, and detoxification, WAISMANN METHOD® offers a variety of programs from rapid opiate detoxification under sedation, to medically assisted detoxification and o...

North American Scientific

Our Mission To pursue with passion the development and introduction of innovative new products that empower physicians and patients with individualized, life-saving treatment solutions. Company Overview Little more than ten years ago, radiation oncology was as much a source of frustration as of hope for its dedicated professionals. Physicians had to face the fact that they often did more harm...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

The HSC Foundation

The HSC Foundation (HSCF) is dedicated to improving access to services for individuals who face challenging social and health care barriers due to disability and chronic illness. It puts a particular emphasis on youth, especially those who are transitioning to adulthood. The HSC Foundation serves as the supporting organization to three healthcare nonprofits. To learn more about The HSC Foundatio...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Lightlake Therapeutics Inc

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Other significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be compl...

Lightlake Therapeutics Inc.

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Other significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be compl...

Cyberonics Incorporated

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, Cyberonics has emerged as a leader in the neuromodulation industry. The VNS Therapy System uses a surgically implanted medical device that delivers elec...

S.T.A.R.S. Healthcare

S.T.A.R.S. Healthcare helps put people on the road to better health and better quality of life by providing superior sleep testing and respiratory services to patients in Arizona. At S.T.A.R.S. sleep centers, patients complete a comprehensive sleep study, obtain an expert diagnosis on a wide range of sleep disorders, and receive recommended treatment from ...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

A Call for a Change

Created in 2017, A Call for a Change is an initiative to ensure patient access to comprehensive pain care, stop the abuse of opioids, and support patient education and activism. Comprised of the leading voices in the opioid crisis, including patients, healthcare practitioners, advocacy groups, law enforcement, industry, insurance companies and politi...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...


More From BioPortfolio on "Opioid patients face several barriers treatment study finds"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks